Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide - Test2 - elhamkhani - TriplyDB

Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide

Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide

http://www.wikidata.org/entity/Q36899427

about

New and emerging disease modifying therapies for multiple sclerosis Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, Fingolimod will change therapeutic paradigm approach Teriflunomide for multiple sclerosis Teriflunomide for multiple sclerosis Teriflunomide for multiple sclerosis Inhibition of human DHODH by 4-hydroxycoumarins, fenamic acids, and N-(alkylcarbonyl)anthranilic acids identified by structure-guided fragment selection Multiple sclerosis--new treatment modalities Development of oral immunomodulatory agents in the management of multiple sclerosis Leflunomide reduces proliferation and induces apoptosis in neuroblastoma cells in vitro and in vivo Proteome analysis of Aspergillus fumigatus identifies glycosylphosphatidylinositol-anchored proteins associated to the cell wall biosynthesis.The role of the T cell in autoimmune inflammation.Glucan synthase complex of Aspergillus fumigatus.An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors.Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tablets Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects.Inhibition of p70 S6 kinase (S6K1) activity by A77 1726 and its effect on cell proliferation and cell cycle progress.Oral disease-modifying therapies for multiple sclerosis.Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens.A refined analysis of superoxide production by mitochondrial sn-glycerol 3-phosphate dehydrogenase.Immunotherapy for De Novo renal transplantation: what's in the pipeline?An update of teriflunomide for treatment of multiple sclerosis.Review of teriflunomide and its potential in the treatment of multiple sclerosis.New oral drugs for multiple sclerosis.Teriflunomide and its mechanism of action in multiple sclerosis.Pathophysiology of multiple sclerosis and the place of teriflunomide.Emerging oral drugs for relapsing-remitting multiple sclerosis.Emerging disease-modifying therapies in multiple sclerosis.Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis.Disease modification in multiple sclerosis: an update.Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar.Leflunomide suppresses growth in human medullary thyroid cancer cells.In vitro evaluation of physiologically relevant concentrations of teriflunomide on activation and proliferation of primary rodent microglia.Leflunomide inhibits transendothelial migration of peripheral blood mononuclear cells.Teriflunomide attenuates immunopathological changes in the dark agouti rat model of experimental autoimmune encephalomyelitis.Suppressive effect of leflunomide metabolite (A77 1726) on metalloproteinase production in IL-1beta stimulated rheumatoid synovial fibroblasts.Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis.Teriflunomide promotes oligodendroglial differentiation and myelination.Control of hyperglycemia in male mice by leflunomide: mechanisms of action.

P2860

Q22242305-04E7C401-8772-4E76-B780-5D55F6AC52DA Q22305854-973A1627-EDB3-46FF-B320-AB67A3D4D199 Q24186016-9A71F9D9-6F06-4536-8AEF-A280CE41FA49 Q24198146-F671F426-5F9C-437B-AE91-64624F723528 Q24202177-C0E156D9-820A-40DB-B603-2D911D0B91CB Q27660047-D305A3CF-1C14-48DD-84D8-2E96D16C5742 Q28072906-6E0967AF-1639-4536-AA40-B50FD1169E0C Q28388704-A1462AFE-DB3E-4EB3-BAE9-C49CA7ED922F Q28535313-FB705AC4-379E-4476-A444-9F0B7EC092F6 Q30712261-012FCF79-82E0-40D7-B7DB-0D8BC73BD8F6 Q33709343-92D2624B-2F60-47D8-B3EE-119F739C71FD Q33995915-7C4C1D3F-BAB1-422A-A0C8-1577D5F927DA Q34066654-BB8FB9BD-FCA9-4161-A4F4-C5A4632E8719 Q34133316-0067F25E-0114-4B4A-A916-0FADDD669476 Q34153221-DE4151D1-FE5B-4456-8B7E-3CFA51C61B2C Q34389332-5E791A8B-1329-4616-9580-18411421D12C Q34417518-9C3252F7-0171-4E79-837D-F3EDC49FE86D Q34996562-C87F53E6-634A-43F8-8F03-C857DA2E474B Q35105760-71E39918-810E-4024-B9F0-119C11504394 Q36466769-858A4B31-B168-4069-989D-CFBA29AC4E1C Q36595129-98356D2D-B7BE-4866-BFED-61965D9726A2 Q36906008-E431BD54-FCFB-4629-818C-9273883DEB96 Q37235715-4D9E10A6-4104-422E-B5AC-CFC91AD4E4BA Q37625921-924EF1D5-23D5-4D01-902A-876B89DA7A28 Q37730005-CED4F999-35FE-4314-9E75-36EDD57E60C5 Q37794267-7A6B1D7E-E09F-4838-BCA4-C2A5EBC99524 Q37965547-A85C42EF-55B9-4503-86FD-B3C0F8113A76 Q37994555-53A558EF-6F2F-497E-AC1B-7700E7AD5D7B Q38107524-BA3C0BE7-0076-4033-8392-C30CBAA7C2CE Q38117110-9379BBCB-C6C5-4B21-AA48-528A8A934B75 Q38150823-D3A14E8B-D846-4F1B-9D94-E4BD11D2C632 Q39021942-0A335B47-C4C5-488F-9E71-69F319D7606C Q39132342-28E18923-E32D-4DDE-BBED-869516798A9B Q41167409-712B4C15-BD09-4185-A333-02AF95A58EFE Q41823791-5646E633-811C-4A39-9793-AEA4A7EA5C96 Q41877062-12477122-06CD-422A-9591-C163BF8C0FAC Q45024320-D2727ED6-6021-4016-B5BA-7FE73B3603C9 Q46147015-6C6A476D-A5B3-4AEC-B312-003C36BC1B03 Q52657615-77472D85-201F-43A6-B269-CF0DDA90DB06 Q52678340-459DD787-FFDD-44F0-87BF-291B5A00A3F3

P2860

Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide

http://www.wikidata.org/entity/Q36899427

description

1998 nî lūn-bûn

@nan

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu

1998年论文

@zh

1998年论文

@zh-cn

name

Purification of human dihydro- ...... tive metabolite of leflunomide

@en

type

label

Purification of human dihydro- ...... tive metabolite of leflunomide

@en

prefLabel

Purification of human dihydro- ...... tive metabolite of leflunomide

@en

P1433

Q36899427-495AC7A7-926B-4DC7-92DF-11A1B28E2AA3

P1476

Q36899427-AC8CA26D-7013-4E35-92E8-13F6156B8AC9

P2093

Q36899427-1385B68A-F876-42C6-ADBD-8C2FADD141C9

Q36899427-424DDDEB-0DF0-4F29-A2C3-E2A37F432FC1

Q36899427-4E43C396-7F11-46BF-97F9-42696B09D45F

Q36899427-5A09E988-DEE3-4B00-B696-239AC549C07F

Q36899427-5A97ACC2-3D78-4CBB-9276-EFE0F4FE35A8

Q36899427-92FAC8B4-EDCE-45A9-92FA-68D43B69FA35

Q36899427-A29E36B5-D04F-4051-8B88-C8EDECCE3492

Q36899427-B20348C5-428B-48E4-8E99-7DBF48F4F427

Q36899427-C5CFE679-8A69-4782-BF90-B4305FB30713

Q36899427-EE2FFCD8-707A-4267-A796-0870E8D9EB9A

P2860

Q36899427-058CC401-B65C-4166-B986-6FA45F7B7B0A

Q36899427-1A83FCA8-D61A-4559-8155-2A817995A748

Q36899427-213E03BE-F9EA-4A79-AACF-A431C8936E81

Q36899427-2E959AA0-7795-40A1-A780-9E7E5B05FB18

Q36899427-522270DC-89C5-4AC9-99D7-A84BF454F5E2

Q36899427-5CD7CA75-AE0F-4AB4-B530-339169B7A1B9

Q36899427-A5AD3010-3B25-4DD2-BFB7-5FBB22296DCC

Q36899427-BEE75CBC-C1CD-44D4-8EE9-4BF4A59422B9

Q36899427-C31CF122-97E0-470F-A285-C229AEA5A104

Q36899427-D6115F5A-2FD1-4A5A-B74F-3C17AE779A41

P304

Q36899427-F2D00AD9-398E-4971-955C-734D7FAEB40D

P31

Q36899427-98C4F247-21E3-4BDD-9CC0-4CF292AD3354

P356

Q36899427-F9ADBE78-4807-4A51-BE63-E6D073E27F3C

P407

Q36899427-F2366007-1A7F-4134-ABA4-85D6D5C9B11D

P478

Q36899427-07A20F10-89C1-4F28-95B8-9EA25BAE0AFB

P577

Q36899427-CCB20B6E-A6D1-4C39-9E05-6247A06018AC

P5875

Q36899427-2FDEC412-7EBA-4A31-9A4F-3ADCEED249FE

P698

Q36899427-7035FAA5-98FC-45BD-B52A-6177C0CB9A92

P932

Q36899427-250E3235-E6A7-4177-827B-240D67551BE8

P356

P1433

Biochemical Journal

P1476

Purification of human dihydro- ...... tive metabolite of leflunomide

@en

P2093

Bruneau JM

http://www.w3.org/2001/XMLSchema#string

Fudali C

http://www.w3.org/2001/XMLSchema#string

Kuo EA

http://www.w3.org/2001/XMLSchema#string

Robson PA

http://www.w3.org/2001/XMLSchema#string

Ruuth E

http://www.w3.org/2001/XMLSchema#string

Sautès C

http://www.w3.org/2001/XMLSchema#string

Spinella-Jaegle S

http://www.w3.org/2001/XMLSchema#string

Westwood R

http://www.w3.org/2001/XMLSchema#string

Williamson RA

http://www.w3.org/2001/XMLSchema#string

Woodward K

http://www.w3.org/2001/XMLSchema#string

P2860

Cleavage of structural proteins during the assembly of the head of bacteriophage T4

Molecular cloning and sequence analyses of rat liver dihydroorotate dehydrogenase

A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids

Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection.

Purification and properties of the bovine liver mitochondrial dihydroorotate dehydrogenase.

In vitro and in vivo studies on the combination of Brequinar sodium (DUP-785; NSC 368390) with 5-fluorouracil; effects of uridine

Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound.

Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.

Inhibition of dihydroorotate dehydrogenase activity by brequinar sodium.

Cloning and sequencing of a human cDNA coding for dihydroorotate dehydrogenase by complementation of the corresponding yeast mutant.

P304

299-303

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1042/BJ3360299

http://www.w3.org/2001/XMLSchema#string

P407

P478

336 ( Pt 2)

http://www.w3.org/2001/XMLSchema#string

P577

1998-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13465506

http://www.w3.org/2001/XMLSchema#string

P698

9820804

http://www.w3.org/2001/XMLSchema#string

P932

1219871

http://www.w3.org/2001/XMLSchema#string